Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution

University Hospital, Lille84 enrolled

Overview

Developing a genetic study on localized or locally advanced prostate cancer. The aim of the study is to identify genomic alteration predictive of metastatic recurrence in the context of primary heterogeneity, by using the next generation sequencing (NGS) techniques. Identifying such biomarkers may be useful to detect a higher relapse risk, and thus lower the mortality rate.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Prostatic Neoplasms

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients managed by radical prostatectomy for prostate cancer between 2000 and 2016. * Follow up \> 6 years * Negative pre surgical extension assessment * Prognostic Grade Groups (OGG) III-IV-V * Biochemical recurrence defined by 2 consecutive PSA rises ≥ 0,2 ng/mL * Metastasis positive imaging Exclusion Criteria: * Neoadjuvant therapy * Follow up \< 6 years * Prognostic Grade Groups (PGG) I-II * Biochemical recurrence with metastasis negative imaging

Locations (1)

Hôpital Claude Huriez, CHRU

Lille, France

RECRUITING

Outcomes

Primary Outcomes

The genetic alteration frequencies of TMPRSS2-ERG gene fusion

Time frame: Baseline

Secondary Outcomes

Frequency of amplification of proto-oncogenes (MYC, AR, PIK3CA),

Time frame: Baseline

Frequency of mutations or deletions of tumor suppressor genes (PTEN, TP53, NKX3-1),

Time frame: Baseline

Frequency of point mutations modifying protein function (SPOP)

Time frame: Baseline

Central Contacts

Arnauld Villers, MD,PhD

CONTACT

3 20 44 42 35 arnauld.villers@chru-lille.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.